- Previous Close
0.0002 - Open
0.0002 - Bid 0.0040 x --
- Ask 0.0047 x --
- Day's Range
0.0002 - 0.0002 - 52 Week Range
0.0001 - 0.0990 - Volume
1,010 - Avg. Volume
2,344 - Market Cap (intraday)
8,070 - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3900 - Earnings Date Apr 28, 2025 - May 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
nemauramedical.comRecent News: NMRD
View MorePerformance Overview: NMRD
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NMRD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NMRD
View MoreValuation Measures
Market Cap
8.07k
Enterprise Value
19.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-81.19%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.65M
Diluted EPS (ttm)
-0.3900
Balance Sheet and Cash Flow
Total Cash (mrq)
137.42k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-10.07M